

Burosumab

Cat. No.:	HY-P9939
CAS No.:	1610833-03-8
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia ^{[1][2]} .
IC ₅₀ & Target	FGF23 ^[1]

REFERENCES

[1]. Schindeler A, et al. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children. *Front Endocrinol (Lausanne)*. 2020 May 28;11:338.

[2]. Colangelo L, et al. Appropriate dosing of burosumab in tumor-induced osteomalacia. *Osteoporos Int*. 2022 Dec 1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA